Text Size

Dermacyd Silver Floral (Lactic Acid) - Acceptability.

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00933569
First received: July 3, 2009
Last updated: September 13, 2010
Last verified: September 2010
History of Changes
  Purpose

Primary Objective:

To prove the safety of the gynaecological formulation in normal conditions of use.


Condition Intervention Phase
Hygiene
 Drug: LACTIC ACID(ND)
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up Dermacyd Silver Floral (Lactic Acid).

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Evaluation of the absence of irritation and the good acceptability by using one specific scale which describes the intensity of the reaction. [ Time Frame: From the treatment start to the end of the study (treatment period 21 days) ] [ Designated as safety issue: No ]

Enrollment: 31
Study Start Date: June 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dermacyd Silver Floral (Lactic Acid)
Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
 Drug: LACTIC ACID(ND)
treatment period: 21 consecutive days

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Integral vaginal mucosa in the product analysis region
  • Use the same category of cosmetics products
  • Willingness in following the study procedures and to be present in the clinic at the days and scheduled time

Exclusion criteria:

  • Use of Anti-inflammatory, immunossupression or antihistaminics drugs
  • Allergic or atopic history to cosmetics products
  • Cutaneous active disease (local and/or general) in the evaluated area
  • Disease which can cause immunosuppresion, such as diabetes, HIV
  • Endocrinology pathology such as thyroid gland, ovary and adrenal gland
  • Intensive solar exposure until 15 days before evaluation
  • Gynecological treatment until four weeks before the study
  • Other reason considered by the investigator as a reason for not being included.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00933569

Locations
Brazil
Sanofi-Aventis Administrative Office
Sao Paulo, Brazil
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Jaderson Lima Sanofi
  More Information

No publications provided

Responsible Party: Medical Affairs Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00933569     History of Changes
Other Study ID Numbers: LACAC_L_04838
Study First Received: July 3, 2009
Last Updated: September 13, 2010
Health Authority: Brazil: National Health Surveillance Agency

ClinicalTrials.gov processed this record on June 17, 2013